Lupin has announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States. This product is bioequivalent to Victoza and indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes. The U.S. market had estimated annual sales of USD 350 million.
Liraglutide Injection Available
Lupin Limited has officially launched Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the U.S. This announcement was made on October 3, 2025.
Product Details and Indication
The newly launched Liraglutide Injection is bioequivalent to Victoza® Injection, 18 mg/3 mL (6 mg/mL). It is prescribed in addition to diet and exercise to help improve blood sugar control in adults and children aged 10 years and older who have type 2 diabetes.
Market Impact
According to data from August 2025, the U.S. market for Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen (RLD Victoza®), had an estimated annual sale of USD 350 million.
Executive Commentary
Spiro Gavaris, President – U.S. Generics, Lupin, stated, “We are pleased to launch Liraglutide Injection in the U.S. This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients.”
Source: BSE
